Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327642 | 0.90 | ALDH1A1 (0.45) | LMNAALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL3326854 | 0.90 | KMT2A (0.40) | TSHRUSP2ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4636239 | 0.86 | PTGDR2 (0.35) | ALDH1A1TDP1MAPT | |
| SCHEMBL4636280 | 0.85 | ALDH1A1 (0.45) | MAPK1LMNATSHRUSP2ALDH1A1 | |
| SCHEMBL4636111 | 0.81 | MAPT (0.38) | MAPK1LMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4727157 | 0.80 | USP2 (0.41) | MAPK1LMNATSHRUSP2ALDH1A1 | |
| SCHEMBL3327671 | 0.80 | MAPT (0.33) | LMNATSHRSMN1; SMN2TDP1MAPT | |
| SCHEMBL3327423 | 0.80 | CNR1 (0.39) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL3963643 | 0.76 | PTGDR2 (0.42) | MAPK1ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3329225 | 0.76 | ALDH1A1 (0.39) | LMNATSHRUSP2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-2136804-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Argenta Oral Therapeutics Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113965-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | HRH1, HRH4, HRH2 | MAPK1 2061/4885LMNA 2881/4885TSHR 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.